Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/4/2018
SIETES contiene 92257 citas

 
 
 1 a 20 de 839 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016. Morbidity and Mortality Weekly Report 2018;67:30 de marzo. [Ref.ID 102488]
2.Enlace a cita original Cita con resumen
Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, Gissler M, Hernández-Díaz S, Karlsson P, Karlstad Ø, Kieler H, Lahesmaa-Korpinen AM, Mogun H, Nørgaard M, Reutfors J, Sørensen HT, Zoega H, Bateman BT. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry 2017:13 de diciembre. [Ref.ID 102188]
3. Cita con resumen
Anónimo. Guanfacine et déficit de l'attention avec hyperactivité. Prescrire 2017;37:329-32. [Ref.ID 101647]
4. Cita con resumen
Anónimo. Pitolisant et narcolepsie. Prescrire 2017;37:333-5. [Ref.ID 101643]
7. Cita con resumen
Chanq Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H, D'Onofrio BM. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry 2017;74:597-603. [Ref.ID 101569]
8. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
9. Cita con resumen
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]
10.Enlace a cita original Cita con resumen
Hoshen MB, Benis A, Keyes KM, Zoëga H. Stimulant use for ADHD and relative age in class among children in Israel. Pharmacoepidemiol Drug Saf 2016;25:652-60. [Ref.ID 100395]
11. Cita con resumen
Jackson JW. The cardiovascular safety of methylphenidate. BMJ 2016;353:i2874. [Ref.ID 100356]
12. Cita con resumen
Imbernón-Moya A, Chico R, Aguilar-Martínez A. Manifestaciones cutáneas y mucosas asociadas al consumo de cocaína. Med Clin (Barc) 2016;146:544-9. [Ref.ID 100354]
14. Cita con resumen
16. Cita con resumen
Anonimo. FDA approves chewable version of AD/HD stimulant medication. DIA Daily 2015:1. [Ref.ID 99726]
17.Tiene citas relacionadas Cita con resumen
Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Homskov M, Skoog M, Nilausen TD, Magnusson FL, Zwi M, Gillies D, Rosendal S, Groth C, Rasmussen KB, Gauci D, Kirubakaran R, Forsbol B, Simonsen E, Gluud C. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 2015;351:h5203. [Ref.ID 99705]
18. Cita con resumen
Hawkes N. Sixty seconds on . . . ADHD. BMJ 2015;351:h6294. [Ref.ID 99703]
19.Tiene citas relacionadas Cita con resumen
Fazel M. Methylphenidate for ADHD. BMJ 2015;351:h5875. [Ref.ID 99702]
20. Cita con resumen
Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics 2015;136:1144-53. [Ref.ID 99685]
Seleccionar todas
 
 1 a 20 de 839 siguiente >>